DDX53 and colorectal cancer: Similarly, AM-1882 treatment promoted the protein expression of p21, and suppressed the protein expression of CDK1 and cyclin B1 in NCI-H747, SW620 and CT26 CIN+ colorectal cancer cells (Fig. 3C).